NMDA Receptor Activity in Neuropsychiatric Disorders
暂无分享,去创建一个
Shaheen E. Lakhan | S. Lakhan | Mario Caro | Norell Hadzimichalis | M. Caro | Norell M. Hadzimichalis
[1] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[2] B. Diamond,et al. Mutational analysis of an autoantibody: differential binding and pathogenicity , 1994, The Journal of experimental medicine.
[3] V. Arolt,et al. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex , 2003, Psychopharmacology.
[4] D. Butterfield,et al. The Glutamatergic System and Alzheimer’s Disease , 2003, CNS drugs.
[5] S. Lipton,et al. Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.
[6] John Hardy,et al. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau , 1998, Nature Neuroscience.
[7] D. Javitt,et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.
[8] Stephen M. Stahl. Depression and Bipolar Disorder. Stahl's Essential Psychopharmacology , 2008 .
[9] J. Cummings,et al. Huntington's disease. , 1997, The Psychiatric clinics of North America.
[10] A. Deutch,et al. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[11] P. Reddy,et al. Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.
[12] B. Diamond,et al. Peptide inhibition of glomerular deposition of an anti-DNA antibody. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] G. Rosenbaum,et al. Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.
[14] B. Volpe,et al. Cognition and immunity; antibody impairs memory. , 2004, Immunity.
[15] R. Ho,et al. Clinical implications of neuropsychiatric systemic lupus erythematosus , 2009 .
[16] D R Medoff,et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.
[17] Francesca Bosetti,et al. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? , 2002, Archives of general psychiatry.
[18] M. Petri,et al. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. , 2011, Seminars in arthritis and rheumatism.
[19] NMDA Receptor Subunits: Function and Pharmacology , 2007 .
[20] J. Coyle,et al. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. , 1976, Nature.
[21] C. Correll,et al. PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .
[22] Julie Harris,et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model , 2011, Nature.
[23] Nanxin Li,et al. mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.
[24] P. Paoletti,et al. NMDA receptor subunits: function and pharmacology. , 2007, Current opinion in pharmacology.
[25] H. Praag,et al. The role of serotonin in schizophrenia , 1995, European Neuropsychopharmacology.
[26] G. Griebel,et al. The Glycine Transporter-1 Inhibitor SSR103800 Displays a Selective and Specific Antipsychotic-like Profile in Normal and Transgenic Mice , 2010, Neuropsychopharmacology.
[27] M. Fava,et al. Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D , 2008, Journal of General Internal Medicine.
[28] Carlos A. Zarate,et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders , 2008, Nature Reviews Drug Discovery.
[29] Beate D. Kretschmer,et al. Modulation of the Mesolimbic Dopamine System by Glutamate , 1999, Journal of neurochemistry.
[30] R. Malinow. New developments on the role of NMDA receptors in Alzheimer's disease , 2012, Current Opinion in Neurobiology.
[31] J. Lindenmayer. New pharmacotherapeutic modalities for negative symptoms in psychosis , 1995, Acta psychiatrica Scandinavica. Supplementum.
[32] E. Salińska,et al. N-methyl-d-aspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: in vitro--superfusion study. , 2002, Folia neuropathologica.
[33] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[34] M. Millan. N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives , 2005, Psychopharmacology.
[35] D. Goff,et al. Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.
[36] W. Fleischhacker. New drugs for the treatment of schizophrenic patients , 1995, Acta psychiatrica Scandinavica. Supplementum.
[37] C. Masters,et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[38] Carlos Cepeda,et al. Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.
[39] Alexander Alanine,et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. , 2010, Journal of medicinal chemistry.
[40] Paul J Carlson,et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.
[41] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[42] A. Popescu,et al. Neuropsychiatric Systemic Lupus Erythematosus , 2011, Current neuropharmacology.
[43] J. Coyle,et al. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.
[44] S. Stahl,et al. The dopamine hypothesis of schizophrenia: a review. , 1976, Schizophrenia bulletin.
[45] H. H. Kornhuber,et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.
[46] S. Pirkola,et al. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. , 2013, The Journal of clinical psychiatry.
[47] M. Travis,et al. Published by The Royal College of Psychiatrists , 2022 .
[48] J. Kennedy,et al. N-methyl-d-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels , 2006, Schizophrenia Research.
[49] T. Pawełczyk,et al. [Risk factors of schizophrenia development in patients with amphetamines dependence and psychosis (amphetamine-induced psychosis and schizophrenia), and without psychosis]. , 2012, Psychiatria polska.
[50] S. Stahl,et al. Glutamate Neurocircuitry: Theoretical Underpinnings in Schizophrenia , 2012, Front. Pharmacol..
[51] A. V. Kenny,et al. Assembly and forward trafficking of NMDA receptors (Review) , 2008, Molecular membrane biology.
[52] B. Laube,et al. Formation of NR1/NR2 and NR1/NR3 Heterodimers Constitutes the Initial Step in N-Methyl-D-aspartate Receptor Assembly* , 2008, Journal of Biological Chemistry.
[53] Antonius M. J. VanDongen,et al. Biology of the NMDA receptor , 2008 .
[54] J. Kemp,et al. NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.
[55] S. Lechner. Glutamate-based therapeutic approaches: inhibitors of glycine transport. , 2006, Current opinion in pharmacology.
[56] R. Kahn,et al. The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.
[57] Lisa Chang,et al. Chronic Lithium Chloride Administration Attenuates Brain NMDA Receptor-Initiated Signaling via Arachidonic Acid in Unanesthetized Rats , 2006, Neuropsychopharmacology.
[58] K. Manaye,et al. Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain , 2006, Brain Research Bulletin.
[59] J. Tsien,et al. Memory and the NMDA receptors. , 2009, The New England journal of medicine.
[60] D. Rosielle,et al. Psychiatry , 1905, NeuroImage.
[61] J. Mogensen,et al. Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests , 2013, Neuroscience Letters.
[62] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[63] T. Steckler,et al. NMDA receptors, cognition and schizophrenia – Testing the validity of the NMDA receptor hypofunction hypothesis , 2012, Neuropharmacology.
[64] D. D’Souza,et al. Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence , 2012, Neuropsychopharmacology.
[65] M. Dalva,et al. EphB Controls NMDA Receptor Function and Synaptic Targeting in a Subunit-Specific Manner , 2011, The Journal of Neuroscience.
[66] A. Fersht,et al. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[67] K. Gogas. Glutamate-based therapeutic approaches: NR2B receptor antagonists. , 2006, Current opinion in pharmacology.
[68] A. Young,et al. A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.
[69] B. Diamond,et al. A novel class of anti-DNA antibodies identified in BALB/c mice , 1991, The Journal of experimental medicine.
[70] B. Volpe,et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment , 2006, Proceedings of the National Academy of Sciences.